Gilead's Trodelvy snags vital breast cancer nod

[cafead]

via The FDA has approved Trodelvy for previously treated HR-positive, HER2-negative breast cancer, Gilead said Friday. To be eligible for the therapy, patients must have tried endocrine therapy and at least two additional therapies in the metastatic setting.

article source